Bispecific antibody · Antagonist of epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGFB1) · developed by Bicara Therapeutics
Ficerafusp alfa is a bifunctional monoclonal antibody that binds both EGFR and TGF-beta. It blocks EGFR-mediated signaling and prevents TGF-beta activation, inhibiting tumor cell proliferation. It is studied in squamous cell carcinomas of the head and neck, lung, and anal canal, as well as colorectal, ovarian, and pancreatic cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06788990 | Phase 2/3 | Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | BCAX |
| NCT04429542 | Phase 1 | Head and Neck Squamous Cell Carcinoma | Recruiting | BCAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Carcinoma, Squamous CellColorectal CancerCutaneous Squamous Cell CarcinomaEGFR AmplificationEpithelial Ovarian CancerHead and Neck NeoplasmsHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaPancreas CancerRecurrent Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalSquamous Cell Carcinoma of Head and NeckSquamous Cell Carcinoma of the Lung
Updated Oct 3, 2026. Something wrong or missing? Report it on the BCAX page.
See BCAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BCAX catalysts and pipeline →